# A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

> **NCT02367456** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 73 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** PF-04449913 (Glasdegib)
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT02367456
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-28
- **Primary completion:** 2020-01-29
- **Final completion:** 2022-03-07
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367456, "A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02367456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*